“Deidentified” data on individual participants in more than 200 GlaxoSmithKline-sponsored clinical trials are now available to independent researchers, company officials said.
And by the end of the year, the database is likely to include patient-level data from some 400 interventional trials, according to Perry Nisen, MD, PhD, and Frank Rockhold, PhD, of GSK’s research division in King of Prussia, Pa.
{iframe}http://www.medpagetoday.com/PublicHealthPolicy/ClinicalTrials/40769{/iframe}